| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Over the last 12 months, insiders at Eledon Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Eledon Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eledon Pharmaceuticals, Inc. have bought $2.32M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,927,937 shares for transaction amount of $4.57M was made by BVF PARTNERS L P/IL (10 percent owner) on 2024‑05‑09.
| 2024-05-09 | BVF PARTNERS L P/IL | 10 percent owner | 1.93M 7.8677% | $2.37 | $4.57M | +29.58% | ||
| 2023-05-05 | BVF PARTNERS L P/IL | 10 percent owner | 1.98M 11.9399% | $2.31 | $4.57M | -41.79% | ||
| 2022-11-23 | Perrin Steven | President | 1,000 0.0072% | $2.60 | $2,597 | -23.11% | ||
| 2021-12-20 | Gros David-Alexandre C | Chief Executive Officer | 2,000 0.0135% | $4.48 | $8,960 | -30.07% | ||
| 2021-08-17 | Gros David-Alexandre C | Chief Executive Officer | 4,000 0.0262% | $6.21 | $24,840 | -39.06% | ||
| 2021-06-11 | Little Paul Sean | CHIEF FINANCIAL OFFICER | 10,000 0.0681% | $8.87 | $88,700 | -46.53% | ||
| 2021-06-09 | Gros David-Alexandre C | Chief Executive Officer | 3,000 0.0203% | $8.01 | $24,030 | -40.88% | ||
| 2020-12-02 | Sale | OrbiMed Israel GP Ltd. | 10 percent owner | 103,200 6.5689% | $21.60 | $2.23M | -63.07% | |
| 2020-10-30 | Sale | Logos Global Management LP | 10 percent owner | 12,969 0.9094% | $26.64 | $345,559 | -62.38% | |
| 2020-10-30 | Logos Global Management LP | 10 percent owner | 92,040 6.1626% | $25.44 | $2.34M | -62.38% | ||
| 2019-05-21 | Sale | FLESHER GREGORY J. | Chief Executive Officer | 2,937 0.025% | $1.91 | $5,614 | -66.49% | |
| 2019-05-21 | Sale | TURKEL CATHERINE C. | President | 1,914 0.0163% | $1.91 | $3,658 | -66.49% | |
| 2019-05-21 | Sale | Kuwahara Jon | See Remarks | 1,058 0.009% | $1.91 | $2,022 | -66.49% | |
| 2019-05-20 | Sale | FLESHER GREGORY J. | Chief Executive Officer | 11,701 0.1045% | $1.96 | $22,953 | -65.78% | |
| 2019-05-20 | Sale | TURKEL CATHERINE C. | President | 7,623 0.068% | $1.96 | $14,953 | -65.78% | |
| 2019-05-20 | Sale | Kuwahara Jon | See Remarks | 4,218 0.0377% | $1.96 | $8,274 | -65.78% | |
| 2019-05-02 | OrbiMed Israel GP Ltd. | 646,204 6.2443% | $3.10 | $2M | -76.19% | |||
| 2019-05-02 | Chimovits Erez | director | 646,204 6.2443% | $3.10 | $2M | -76.19% | ||
| 2019-04-30 | Sale | LIFESCI INDEX PARTNERS LLC | 10 percent owner | 200 0.0017% | $2.70 | $540 | -75.47% | |
| 2018-09-12 | TURKEL CATHERINE C. | President | 16,632 0.1711% | $5.02 | $83,476 | -44.40% |
| Harrison Seth Loring | 7912079 13.198% | $12.5M | 1 | 0 | ||
| Novartis Bioventures Ltd | 10 percent owner | 4493458 7.4954% | $7.1M | 1 | 9 | |
| Apple Tree Partners II - Annex, L.P. | 3568438 5.9524% | $5.64M | 1 | 0 | ||
| BVF PARTNERS L P/IL | 10 percent owner | 3361803 5.6077% | $5.31M | 2 | 0 | <0.0001% |
| Chimovits Erez | director | 3183314 5.31% | $5.03M | 1 | 0 | <0.0001% |
| Satter Muneer A | 10 percent owner | 1771688 2.9553% | $2.8M | 1 | 0 | |
| LIFESCI INDEX PARTNERS LLC | 10 percent owner | 1065867 1.7779% | $1.68M | 0 | 1 | |
| Logos Global Management LP | 10 percent owner | 224071 0.3738% | $354,032.18 | 1 | 1 | <0.0001% |
| FLESHER GREGORY J. | Chief Executive Officer | 156918 0.2618% | $247,930.44 | 1 | 2 | |
| TURKEL CATHERINE C. | President | 88662 0.1479% | $140,085.96 | 4 | 2 | <0.0001% |
| OrbiMed Israel GP Ltd. | 10 percent owner | 73650 0.1229% | $116,367.00 | 1 | 1 | <0.0001% |
| Kalowski Lee | Chief Financial Officer | 40953 0.0683% | $64,705.74 | 0 | 4 | |
| OCAMPO CHRISTINE | See Remarks | 21590 0.036% | $34,112.20 | 1 | 0 | |
| Morrison Jodie Pope | President and CEO | 19551 0.0326% | $30,890.58 | 0 | 3 | |
| Buckley Stephen Jr. | director | 11000 0.0183% | $17,380.00 | 2 | 0 | |
| Little Paul Sean | CHIEF FINANCIAL OFFICER | 10000 0.0167% | $15,800.00 | 1 | 0 | <0.0001% |
| Gros David-Alexandre C | Chief Executive Officer | 9000 0.015% | $14,220.00 | 3 | 0 | <0.0001% |
| Kuwahara Jon | See Remarks | 5974 0.01% | $9,438.92 | 0 | 2 | |
| Perrin Steven | President | 1000 0.0017% | $1,580.00 | 1 | 0 | <0.0001% |
| McBride John S. | Chief Operating Officer | 0 0% | $0 | 0 | 4 |
$17,525,882 | 60 | 5.22% | $87.83M | |
$103,288,323 | 51 | 4.78% | $83.61M | |
$4,898,715 | 46 | 40.75% | $110.93M | |
$16,259,194 | 41 | 120.51% | $86.42M | |
$160,539,875 | 21 | -6.57% | $95.2M | |
$38,821,584 | 20 | -2.17% | $86.66M | |
$3,331,968 | 17 | -23.79% | $94.05M | |
$7,733,516 | 17 | 73.42% | $103.31M | |
$277,862 | 15 | 59.79% | $98.58M | |
$245,302 | 15 | -4.08% | $96.47M | |
$18,563,605 | 15 | 48.91% | $91.06M | |
Eledon Pharmaceuticals, Inc. (ELDN) | $15,799,576 | 12 | -39.52% | $94.72M |
$145,194 | 11 | -27.37% | $103.25M | |
$135,589,307 | 10 | 32.46% | $100.43M | |
$68,692,148 | 6 | -39.10% | $104.89M | |
$105,079 | 4 | -41.57% | $92.85M | |
$657,791 | 4 | -52.05% | $89.51M | |
$16,554 | 2 | 41.65% | $100.02M | |
$10,096 | 1 | -13.07% | $83.76M |
| Increased Positions | 43 | +40.19% | 7M | +16.16% |
| Decreased Positions | 44 | -41.12% | 11M | -26.95% |
| New Positions | 21 | New | 4M | New |
| Sold Out Positions | 21 | Sold Out | 8M | Sold Out |
| Total Postitions | 106 | -0.93% | 36M | -10.79% |
| Bvf Inc/Il | $10,258.00 | 8.39% | 6.29M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $5,813.00 | 4.76% | 3.57M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $5,648.00 | 4.62% | 3.47M | +210,930 | +6.48% | 2025-09-30 |
| Vanguard Group Inc | $5,326.00 | 4.36% | 3.27M | -50,600 | -1.52% | 2025-09-30 |
| Siren, L.L.C. | $3,379.00 | 2.76% | 2.07M | +1M | +200.33% | 2025-09-30 |
| Zimmer Partners, Lp | $2,975.00 | 2.43% | 1.82M | +844,318 | +86.09% | 2025-09-30 |
| Geode Capital Management, Llc | $2,231.00 | 1.83% | 1.37M | -15,000 | -1.08% | 2025-09-30 |
| Wellington Management Group Llp | $2,093.00 | 1.71% | 1.28M | +1M | New | 2025-09-30 |
| Sphera Funds Management Ltd. | $2,087.00 | 1.71% | 1.28M | -679,377 | -34.67% | 2025-09-30 |
| Ensign Peak Advisors, Inc | $2,062.00 | 1.69% | 1.26M | 0 | 0% | 2025-09-30 |